Diffuse gliomas represent a heterogeneous group of universally lethal brain tumors
characterized by minimally effective genotype-targeted therapies. Recent advances have …

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The
current standard of care involves surgical resection (if possible) followed by concomitant …

Besides the broad development of nanotechnological approaches for cancer diagnosis and
therapy, currently, there is no significant progress in the treatment of different types of brain …

Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain stem tumor and the leading
cause of pediatric cancer-related death. To date, these tumors remain incurable …

Existing drug delivery methods have not led to a significant increase in survival for patients
with malignant primary brain tumors. While the combination of conventional therapies …

Diffuse intrinsic pontine glioma (DIPG) is an incurable malignant childhood brain tumor, with
no active systemic therapies and a 5-year survival of less than 1%. Polyamines are small …

Focused Ultrasound (FUS) in combination with gaseous microbubbles has emerged as a
potential new means of effective drug delivery to the brain. Recent research has shown that …

Hyponatremia is the most common electrolyte disorder, affecting more than 15% of patients
in the hospital. Syndrome of inappropriate antidiuresis (SIAD) is the most frequent cause of …

Physiologically, brain tumors interact with surrounding vascular and glial cells, and change
their responses to survive in brain tissue‐specific microenvironments. A major difficulty in …

Effective intervention is essential to combat the coming epidemic of neurodegenerative (ND)
diseases. Nanomedicine can overcome restrictions of CNS delivery imposed by the blood …